Biopsy
Best to Confirm Breast Cancer Diagnosis
A breast biopsy is the preferred follow-up procedure
to confirm a cancer diagnosis, even though several other test options
exist and may be offered by physicians, according to a report from
the Agency for Healthcare Research and Quality
(AHRQ).
The AHRQ study compared
the effectiveness of biopsy, long considered the "gold standard," with
four other tests.
The other four tests were magnetic resonance imaging,
or MRI; ultrasonography; positron emission tomography (PET) scanning;
and scintimammography, or breast scan.
The report focuses on a very specific question,
says AHRQ Director Dr. Carolyn M. Clancy.
The researchers were addressing whether or not any of the other noninvasive
tests sufficiently are accurate to diagnosis cancer or to rule it out.
A biopsy is accurate but invasive, requiring the
taking of a sample of breast tissue and analyzing it for signs of cancer
in a lab. Because of this, researchers have been searching for noninvasive
tests that would be as accurate.
The four tests assessed in the report, all suggested
as substitutes for biopsies, were not as accurate as a biopsy overall.
The tests studied missed between 4 percent and 9
percent of breast malignancies in women at average risk, the report
found, and probably would miss more cases than that among women at
higher risk of the disease.
How accurate is accurate enough?
"Some experts say a test would have to miss fewer
than 2 percent to be considered sufficiently accurate," says Dr. Clancy.
It is hard to pinpoint the exact accuracy of biopsies,
but a study published last year in the Annals
of Surgery found that the "false-negative" rate for one type
of biopsy, called a "core biopsy," was 6 percent, according to Fran
Visco, the first president and spokeswoman for the National
Breast Cancer Coalition in Washington, D.C.
In the AHRQ report,
the researchers found that the use of MRI missed 38 cancers for every
1,000 women; ultrasound missed 50 tumors for every 1,000 women; and
PET scans missed 76 per 1,000 women.
Scintimammography, a nuclear medicine test method
that uses a small amount of a radioactive substance and a scanner to
detect cancer, missed 93 tumors for every 1,000 women.
The report on the four noninvasive tests is valuable,
explains Visco.
"My interest in the 2006 AHRQ report
focuses on the fact that we move these technologies into clinical practice
when we don't have the data that show they are effective,” notes
Visco. “That adds to healthcare costs and also doesn't serve
women well."
Having access to solid data that proves a test is
accurate will help women and the healthcare system, she says.
Dr. Clancy adds that the findings in this study
provide good information for women to have additional conversations
with their physicians.
If a physician suggests one of the alternate tests
after an abnormal mammogram it would be reasonable to ask for a biopsy
instead of these tests.
Always consult your physician for more information.
|